PCM
IRWD icon

Polymer Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Polymer Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,747
Closed -$164K – 914
2025
Q4 		$164K Buy
+48,747
New +$127K 0.02% 708

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Polymer Capital Management's IRWD Position: Q1 2026 in Review

Polymer Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2026, closing a stake of 48,747 shares — an estimated $164K sold.

Polymer Capital Management first reported a position in IRWD in Q4 2025 and held it in 1 quarter. The position peaked at $164K in Q4 2025. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Polymer Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Polymer Capital Management sold 48,747 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $164K.
  • Polymer Capital Management first reported a position in Ironwood Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Polymer Capital Management's Ironwood Pharmaceuticals position peaked at $164K in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.